Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2026
Automated Insulin Delivery Systems in Cystic Fibrosis-Related Diabetes: A Systematic Review and Meta-Analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Souza Bruno L, Abramowitz Jessica, Mirfakhraee Sasan, Tamega Maria E C, Costa Yosteline, Chiappa Gaspar R, Abreu Marconi
Аннотация
OBJECTIVES: To assess the effects of automated insulin delivery systems (AIDs) on glycemic control and selected metabolic and pulmonary outcomes in people with cystic fibrosis related diabetes (pwCFRD).
METHODS: We searched MEDLINE (via PubMed), Embase, and Cochrane Library for studies of AIDs in pwCFRD. Eligible studies included at least 14 days of follow-up and reported continuous glucose monitoring outcomes. The primary outcome was time in range (3.9-10.0 mmol/L or 70-180 mg/dL). Additional outcomes included time above range (>10.0 mmol/L or 180 mg/dL), time below range (<3.9 mmol/L or 70 mg/dL), average glucose, body mass index, and FEV1. We performed single-arm meta-analyses using a random-effects model.
RESULTS: Four studies (n = 69) met inclusion criteria. AIDs increased time in range by 9.55% (95% CI 1.49, 17.61; P = .02) at short-term (14-30 days) and 11.55% (95% CI 5.61, 17.50; P < .001) at long-term (≥12 weeks) follow-up, respectively. Time above range decreased by 8.41% (95% CI -15.59, -1.22; P = .022) and 12.96% (95% CI -17.67, -8.26; P < .001) at short- and long-term, respectively. Average glucose decreased by 1.01 mmol/L (18 mg/dL) (95% CI -1.98, -0.04; P = .042) and 1.12 mmol/L (20 mg/dL) (95% CI -1.70, -0.54; P < .001) at short- and long-term, respectively. AIDs did not change time below range, body mass index, and FEV1.
CONCLUSIONS: AIDs improved glycemic control in pwCFRD without increasing hypoglycemia, with short-term benefits persisting over 12 weeks. Larger randomized trials are needed to confirm these findings.
METHODS: We searched MEDLINE (via PubMed), Embase, and Cochrane Library for studies of AIDs in pwCFRD. Eligible studies included at least 14 days of follow-up and reported continuous glucose monitoring outcomes. The primary outcome was time in range (3.9-10.0 mmol/L or 70-180 mg/dL). Additional outcomes included time above range (>10.0 mmol/L or 180 mg/dL), time below range (<3.9 mmol/L or 70 mg/dL), average glucose, body mass index, and FEV1. We performed single-arm meta-analyses using a random-effects model.
RESULTS: Four studies (n = 69) met inclusion criteria. AIDs increased time in range by 9.55% (95% CI 1.49, 17.61; P = .02) at short-term (14-30 days) and 11.55% (95% CI 5.61, 17.50; P < .001) at long-term (≥12 weeks) follow-up, respectively. Time above range decreased by 8.41% (95% CI -15.59, -1.22; P = .022) and 12.96% (95% CI -17.67, -8.26; P < .001) at short- and long-term, respectively. Average glucose decreased by 1.01 mmol/L (18 mg/dL) (95% CI -1.98, -0.04; P = .042) and 1.12 mmol/L (20 mg/dL) (95% CI -1.70, -0.54; P < .001) at short- and long-term, respectively. AIDs did not change time below range, body mass index, and FEV1.
CONCLUSIONS: AIDs improved glycemic control in pwCFRD without increasing hypoglycemia, with short-term benefits persisting over 12 weeks. Larger randomized trials are needed to confirm these findings.